Superworth

Xencor price to free cash flow XNCR

Market value divided by free cash flow over the last twelve months, since 2015.

Today, Oct 23, 2026
n/m
not a meaningful number
Last meaningful
37.7×
Feb 2025
10-year median
27.0×
10-year range
7.6× to 347×
Peer median
8.1×

Xencor's price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Feb 2025, at 37.7×.

On the days it had one over the last ten years, its median was 27.0×, from 7.6× in Nov 2016 to 347× in Jul 2022.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
202537.7×37.7×57.9×
202458.3×16.9×61.4×
202326.2×21.3×29.2×
202220.6×20.6×347×
2021n/m a value too high to mean anything
202020.5×19.4×35.5×
201933.5×31.5×40.0×
2018n/m a value too high to mean anything
201710.3×8.5×13.1×
201610.3×7.6×95.9×
201526.1×23.1×29.0×

Against its peers

Companies in Drug Manufacturers - General nearest Xencor's size, closest first, today.

CompanyPrice to free cash flow
XNCRXencorn/m
ANIPANI Pharmaceuticals9.6×
HRMYHarmony Biosciencesn/m
PAHCPhibro Animal Health160×
PBHPrestige Consumer Healthcare9.6×
ANABAnaptysbion/m
PCRXPacira BioSciences8.1×
NRIXNurix Therapeutics7.5×
OMEROmerosn/m
AMPHAmphastar Pharmaceuticals7.0×
OGNOrganon6.4×
Peer median8.1×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Xencor

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.